Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone

被引：3
|
作者：
Brose, M. S. [1 ]
Troxel, A. B. [1 ]
Mamtani, R. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS263
引用
收藏
页数：1
相关论文
共 50 条
  • [21] pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer
    Yarchoan, Mark
    Ma, Changqing
    Troxel, Andrea B.
    Stopenski, Stephen J.
    Tang, Waixing
    Cohen, Aaron B.
    Pappas-Paxinos, Marina
    Johnson, Burles A., III
    Chen, Emerson Y.
    Feldman, Michael D.
    Brose, Marcia S.
    HORMONES & CANCER, 2016, 7 (03): : 188 - 195
  • [22] pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer
    Mark Yarchoan
    Changqing Ma
    Andrea B. Troxel
    Stephen J. Stopenski
    Waixing Tang
    Aaron B. Cohen
    Marina Pappas-Paxinos
    Burles A. Johnson
    Emerson Y. Chen
    Michael D. Feldman
    Marcia S. Brose
    Hormones and Cancer, 2016, 7 : 188 - 195
  • [23] COST AND EFFECTIVENESS OF THE USE OF SORAFENIB IN DIFFERENTIATED THYROID CANCER
    Carrasquilla-Sotomayor, M.
    Alvis-Zakzuk, N. J.
    Gomez de la Rosa, F.
    Alvis Zakzuk, J.
    Marrugo Figueroa, R. D.
    Miranda Machado, P.
    Alvis Guzman, N.
    Herran Diazgranado, S. E.
    VALUE IN HEALTH, 2017, 20 (09) : A876 - A876
  • [24] Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    Bianchi, Giulia
    Loibl, Sibylle
    Zamagni, Claudio
    Salvagni, Stefania
    Raab, Guenter
    Siena, Salvatore
    Laferriere, Nicole
    Pena, Carol
    Lathia, Chetan
    Bergamini, Loredana
    Gianni, Luca
    ANTI-CANCER DRUGS, 2009, 20 (07) : 616 - 624
  • [25] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial
    Brose, M. S.
    Nutting, C.
    Jarzab, B.
    Elisei, R.
    Siena, S.
    Bastholt, L.
    de la Fourchardiere, C.
    Pacini, F.
    Paschke, R.
    Shong, Y. K.
    Sherman, S. I.
    Smit, J. W. A.
    Chung, J.
    Kappeler, C.
    Molnar, I.
    Schlumberger, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 130 - 131
  • [26] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial
    Paschke, R.
    Brose, M. S.
    Nutting, C.
    Jarzab, B. J.
    Elisei, R.
    Siena, S.
    Bastholt, L.
    de la Fouchardiere, C.
    Pacini, F.
    Shong, Y. K.
    Sherman, S., I
    Smit, J. W. A.
    Chung, J.
    Siedentop, H.
    Molnar, I
    Schlumberger, M.
    ONKOLOGIE, 2013, 36 : 184 - 184
  • [27] Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
    Cardin, Dana B.
    Goff, Laura
    Li, Chung-I
    Shyr, Yu
    Winkler, Charles
    DeVore, Russell
    Schlabach, Larry
    Holloway, Melanie
    McClanahan, Pam
    Meyer, Krista
    Grigorieva, Julia
    Berlin, Jordan
    Chan, Emily
    CANCER MEDICINE, 2014, 3 (03): : 572 - 579
  • [28] Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.
    Ikeda, Masafumi
    Shimizu, Satoshi
    Sato, Tosiya
    Morimoto, Manabu
    Inaba, Yoshitaka
    Kojima, Yasushi
    Hagihara, Atsushi
    Kudo, Masatoshi
    Nakamori, Shoji
    Kaneko, Shuichi
    Sugimoto, Rie
    Tahara, Toshiyuki
    Ohmura, Takumi
    Yasui, Kohichiroh
    Sato, Keiko
    Ishii, Hiroshi
    Furuse, Junji
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] SORAVE trial: Phase I sorafenib and everolimus in solid tumors
    Nogova, L.
    Scheffler, M.
    Papachristou, I.
    Mattonet, C.
    Krais, R.
    Katay, I.
    Mallmann, P.
    Fuhr, U.
    Dietlein, M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
    Dadu, Ramona
    Devine, Catherine
    Hernandez, Mike
    Waguespack, Steven G.
    Busaidy, Naifa L.
    Hu, Mimi I.
    Jimenez, Camilo
    Habra, Mouhammad A.
    Sellin, Rena V.
    Ying, Anita K.
    Cote, Gilbert J.
    Sherman, Steven I.
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (06): : 2086 - 2094
12345